Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus GENOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus GENOPTIC.
AMIKIN vs GENOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic